Related Experiment Videos
Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study
1Department of Diagnostic Radiology, Uppsala University Hospital, Sweden. chen.wang@radiol.uu.se
Purpose:
To assess the diagnostic efficacy, safety and tolerability of mangafodipir trisodium (MnDPDP, Teslascan) in MR imaging of the liver.
Material And Methods:
Eighty-two patients from 4 centres underwent MR imaging with pre-contrast sequences including T1-weighted SE and GRE, and T2-weighted turbo SE sequences. MnDPDP at a dose of 5 mumol/kg b.w. was administered by slow i.v. infusion, and 20-60 min after infusion the T1-weighted SE and GRE sequences were repeated. Diagnostic efficacy was evaluated by counting the number of lesions and by evaluating whether more information for lesion characterisation was available in post-contrast images. Safety and tolerability were assessed by recording adverse events and infusion-related discomfort.
Results:
Significantly more lesions were found in MnDPDP-enhanced T1-weighted SE and GRE images than in unenhanced images of the same sequences. More lesions were also found in these images compared with T2-weighted images at a level of marginal significance. More information was obtained from MnDPDP-enhanced images in 40 cases. Mild to moderate adverse events were experienced by 17% of the patients.
Conclusion:
MnDPDP-enhanced images can improve lesion detection in the liver and are helpful for lesion characterisation. To obtain optimal diagnostic information of liver lesions T2-weighted images are also valuable. MnDPDP is a safe contrast agent for MR imaging of liver lesions.
Insights
Mangafodipir trisodium (MnDPDP) enhances MR imaging for better liver lesion detection and characterization. This contrast agent is safe and well-tolerated, improving diagnostic information for liver conditions.
Area of Science:
- Radiology
- Medical Imaging
- Hepatology
Background:
- Liver lesion detection and characterization are crucial for diagnosis and treatment planning.
- Magnetic Resonance Imaging (MRI) is a key modality for liver imaging.
- The development of effective contrast agents is essential for improving MRI efficacy.
Purpose of the Study:
- To evaluate the diagnostic performance of mangafodipir trisodium (MnDPDP, Teslascan) in liver MRI.
- To assess the safety and tolerability of MnDPDP as an MRI contrast agent.
- To determine the utility of MnDPDP in enhancing lesion detection and characterization in the liver.
Main Methods:
- Eighty-two patients from four centers underwent liver MRI, including pre-contrast T1-weighted SE, GRE, and T2-weighted turbo SE sequences.
- MnDPDP was administered intravenously at a dose of 5 μmol/kg.
- Post-contrast T1-weighted SE and GRE sequences were repeated 20-60 minutes after infusion for comparison.
Main Results:
- MnDPDP-enhanced T1-weighted images revealed significantly more liver lesions compared to unenhanced images.
- Enhanced images provided more information for lesion characterization in 40 cases.
- Mild to moderate adverse events were reported in 17% of patients, indicating good tolerability.
Conclusions:
- MnDPDP-enhanced MRI improves the detection and characterization of liver lesions.
- T2-weighted imaging remains valuable for comprehensive diagnostic information.
- MnDPDP is a safe and effective contrast agent for liver lesion MRI.